Cryotherapy Post-haemorrhoidectomy (CYPHER) Randomized Controlled Trial

Launched by SINGAPORE GENERAL HOSPITAL · Aug 15, 2023

Keywords

ClinConnect Summary

The CYPHER trial is studying the use of cryotherapy, which involves applying cold temperatures to help reduce pain and inflammation, in patients who are recovering from surgery for hemorrhoids. Hemorrhoids are swollen veins in the anal area that can cause pain and discomfort, and surgery is often needed for more severe cases. This trial aims to see if cryotherapy can help improve pain relief and overall recovery after common surgical procedures for hemorrhoids.

To be eligible for the trial, participants need to be between 21 and 75 years old and have grade 3 or 4 hemorrhoids, which are more serious types that can prolapse, or stick out. People who have had recent anorectal surgery, certain other medical conditions, or are on specific blood-thinning medications may not qualify. Those who join the study can expect to receive either standard care or cryotherapy after their surgery, and researchers will monitor their pain levels and recovery progress. This trial is currently recruiting participants and aims to find a better way to manage postoperative pain for those undergoing hemorrhoid surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age group of patients: 21 to 75 years old
• • 2. Grade 3 (prolapsed but reducible manually) and Grade 4 (prolapsed but irreducible) piles that are symptomatic
• • 3. Patients recruited are to undergo either staple or conventional (Milligan-Morgan or Ferguson) haemorrhoidectomy
• Exclusion Criteria:
• • 1. Grade 1 and 2 haemorrhoids
• • 2. Thrombosed, irreducible piles that require emergency haemorrhoidectomy
• • 3. Patients who had undergone any previous anorectal surgery within 5 years from the date of recruitment
• • 4. Patients with concurrent anorectal pathology (anal fissures, abscess, fistula, tumour, inflammatory bowel disease)
• • 5. Pregnant women
• • 6. Patients with severe medical comorbidities or assessed as ASA 3 and above
• • 7. Patients on long term antiplatelets (aspirin, plavix) and anticoagulation (clexane, warfarin, rivaroxaban, apixaban)